Olon Expands API Production

Olon, an Italian CDMO and API producer, is investing a total of €100 million in 2023 to increase production capacity, in particular at its site in Mulazzano, Lodi province.

As part of the investment, Olon is installing a new mill for grinding finished APIs, which the company said will lift productivity and ensure high particle size standards. “We expect a significant increase in the potential capacity of the site,” said head of global operations Marcello Buson.

In February this year, Olon announced that it had completed a project at its facility in Rodano, Milan, that expanded pilot plant capacity for scaling up highly active APIs. The company has other pilot plants for developing high-potency APIs with which the Rodano plant will be integrated for increased capacity and improved flexibility.

Olon said the investment at Rodano is part of its strategy to implement a highly integrated operating model between both R&D and manufacturing operations, as well as the integration of specific, highly specialized processes consolidated within research and development centers located at sites around the world.

The integration will also be applied to product scale-up projects, which Olon said require the transition from pilot scale to large- and very large-scale production plants that have similar equipment so as to ensure the same level of containment, even for large batch sizes.

Author: Elaine Burridge, Freelance Journalist

Company

Logo:

Olon S.p.A.

Strada Rivoltana, Km 6/7
20053 Rodano (MI)
Italy

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.